Original Article
Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
N Engl J Med 1999; 340:1314-1320April 29, 1999
- Abstract
Background
Women with the polycystic ovary syndrome have insulin resistance and hyperinsulinemia, possibly because of a deficiency of a d-chiro-inositol–containing phosphoglycan that mediates the action of insulin. We hypothesized that the administration of d-chiro-inositol would replenish stores of the mediator and improve insulin sensitivity.
Methods
We measured steroids in serum and performed oral glucose-tolerance tests before and after the oral administration of 1200 mg of d-chiro-inositol or placebo once daily for six to eight weeks in 44 obese women with the polycystic ovary syndrome. The serum progesterone concentration was measured weekly to monitor for ovulation.
Results
In the 22 women given d-chiro-inositol, the mean (±SD) area under the plasma insulin curve after the oral administration of glucose decreased from 13,417±11,572 to 5158±6714 μU per milliliter per minute (81±69 to 31±40 nmol per liter per minute) (P=0.007; P=0.07 for the comparison of this change with the change in the placebo group); glucose tolerance did not change significantly. The serum free testosterone concentration in these 22 women decreased from 1.1±0.8 to 0.5±0.5 ng per deciliter (38±28 to 17±17 pmol per liter) (P=0.006 for the comparison with the change in the placebo group). The women's diastolic and systolic blood pressure decreased by 4 mm Hg (P<0.001 and P=0.05, respectively, for the comparisons with the changes in the placebo group), and their plasma triglyceride concentrations decreased from 184±88 to 110±61 mg per deciliter (2.1±0.2 to 1.2±0.1 mmol per liter) (P=0.002 for the comparison with the change in the placebo group). None of these variables changed appreciably in the placebo group. Nineteen of the 22 women who received d-chiro-inositol ovulated, as compared with 6 of the 22 women in the placebo group (P<0.001).
Conclusions
d-Chiro-inositol increases the action of insulin in patients with the polycystic ovary syndrome, thereby improving ovulatory function and decreasing serum androgen concentrations, blood pressure, and plasma triglyceride concentrations.
Media in This Article
Figure 2
Serum 17α-Hydroxyprogesterone Concentrations in Women with the Polycystic Ovary Syndrome at Base Line and after the Administration of d-Chiro-Inositol or Placebo for Six to Eight Weeks.Figure 1
Serum Luteinizing Hormone Concentrations in Women with the Polycystic Ovary Syndrome at Base Line and after the Administration of d-Chiro-Inositol or Placebo for Six to Eight Weeks.Article Activity
- Article
Insulin resistance and compensatory hyperinsulinemia, which can occur in otherwise normal persons, are risk factors for type 2 diabetes mellitus,1-4 dyslipidemia,5-7 hypertension,5-7 and atherosclerosis5 — a constellation of findings termed syndrome X, or the metabolic syndrome.5 Both are also prominent features of the polycystic ovary syndrome,8-10 a disorder characterized by chronic anovulation and hyperandrogenism that affects approximately 6 percent of women of reproductive age.11 In these women, hyperinsulinemia both inhibits ovulation12 and stimulates ovarian testosterone production13,14; the women also have an increased incidence of impaired glucose tolerance or type 2 diabetes mellitus10,15-17 and the other features of syndrome X.18-22
Some of the actions of insulin may involve low-molecular-weight inositol phosphoglycan mediators. When insulin binds to its receptor, mediators of this class are generated by hydrolysis of glycosylphosphatidylinositol lipids located at the outer leaflet of the cell membrane. Released mediators are then internalized and affect intracellular metabolic processes. Although different species have been identified, an inositol phosphoglycan molecule containing d-chiro-inositol and galactosamine is known to have a role in activating key enzymes that control the oxidative and nonoxidative metabolism of glucose.23
A deficiency of the d-chiro-inositol phosphoglycan mediator of the action of insulin may result in resistance to insulin. Insulin resistance has been linked to decreased urinary excretion of chiro-inositol (a component of the putative d-chiro-inositol phosphoglycan mediator) in primates,24 in humans with impaired glucose tolerance25 or type 2 diabetes mellitus,26 and in nondiabetic first-degree relatives of persons with diabetes.26 The amount of chiro-inositol in muscle is lower in subjects with type 2 diabetes mellitus than in normal subjects.27,28 In a study of rats, administration of d-chiro-inositol decreased hyperglycemia in rats with diabetes and improved glucose tolerance in normal rats.29 In a study of monkeys with varying degrees of insulin resistance, d-chiro-inositol accelerated the disposal of glucose and decreased insulin secretion.29 These observations suggest that the administration of d-chiro-inositol, which is then presumably used in the formation of the active d-chiro-inositol phosphoglycan mediator, may increase insulin sensitivity and improve the action of insulin in insulin-resistant subjects.
In this study we tested the hypothesis that d-chiro-inositol, by virtue of its ability to increase sensitivity to insulin, would have beneficial effects on ovulation and ovarian production of androgens in women with the polycystic ovary syndrome.
Methods
Subjects
We studied 44 women, 18 to 40 years of age, with the polycystic ovary syndrome, indicated by the presence of oligomenorrhea (eight or fewer menstrual periods in the previous year) and hyperandrogenism (high serum concentrations of free testosterone or hirsutism). They were recruited from the Hospital de Clinicas Caracas in Caracas, Venezuela. Other inclusion criteria were obesity, defined as a body-mass index (the weight in kilograms divided by the square of the height in meters) of more than 28, normal results on thyroid-function tests, and normal serum prolactin concentrations. Ultrasonography of the ovaries revealed polycystic ovaries in all the women,30 but this condition was not an inclusion criterion. None of the women had diabetes mellitus, but 10 had impaired glucose tolerance, defined as a serum glucose concentration of at least 140 but less than 200 mg per deciliter (7.8 to 11.2 mmol per liter) two hours after the oral administration of 75 g of glucose.31 None had taken any medications for at least two months. Thirty-two of the women were white, seven Hispanic, two Afro-Hispanic, two Arabic, and one Asian; four women had one child each, and the remainder had no children.
Twenty-two women were randomly assigned to receive d-chiro-inositol (INS-1, Insmed Pharmaceuticals, Richmond, Va.) and 22 to receive placebo in a double-blind trial. The randomization schedule was generated in blocks of four, and the drug and placebo were packaged at the same time and labeled according to subject number. The study was approved by the institutional review boards of the Hospital de Clinicas Caracas and Virginia Commonwealth University, and each woman gave written informed consent.
Design of the Study
At the time of entry into the study, all the women were in the equivalent of the follicular phase of the menstrual cycle, as documented by a serum progesterone concentration below 2.5 ng per milliliter (8.0 nmol per liter). The women came to the hospital after a 12-hour overnight fast, at which time their weight, height, waist-to-hip ratio, and blood pressure while supine were measured. Blood samples were drawn at 8:30, 8:45, and 9 a.m., and equal volumes of serum were pooled for the measurement of serum steroids and sex hormone–binding globulin. At 9 a.m., 75 g of dextrose (Glycolab, Relab Laboratory, Caracas, Venezuela) was given orally. Blood samples were collected after 30, 60, 90, and 120 minutes for the measurement of plasma glucose and insulin.
The women ate a light meal after the oral glucose-tolerance test and returned for a leuprolide stimulation test at 4 p.m. (described below). After this test, the women began to take 1200 mg of d-chiro-inositol or placebo orally once daily. They were instructed not to alter their usual eating habits, physical activity, or lifestyle during the study; they were also advised to refrain from sexual intercourse or to use a barrier method of contraception.
The women returned weekly for measurements of serum progesterone, and ovulation was presumed to have occurred if the value exceeded 8 ng per milliliter (25 nmol per liter). They returned for the second study after six weeks, if they were confirmed to be in the follicular phase of the menstrual cycle by measurement of a low serum progesterone value (<2.5 ng per milliliter). All the studies performed at base line were repeated at this visit. Four women in the d-chiro-inositol group and four women in the placebo group had serum progesterone values in the postovulatory range after six weeks and therefore continued to receive the study treatment or placebo as assigned. Six of these women were studied during week 7 and two women (both treated with d-chiro-inositol) were studied during week 8, when their serum progesterone concentrations were low. No side effects were noted in the women in either group.
Leuprolide Stimulation Test
After base-line blood samples had been obtained at 4 p.m., leuprolide (Lupron, Abbott, Takeda, Japan) was administered subcutaneously at a dose of 10 μg per kilogram of body weight. Blood samples were collected 0.5, 1, 16, 20, and 24 hours after leuprolide administration for measurement of serum luteinizing hormone and 17α-hydroxyprogesterone concentrations. The women ate an evening meal but subsequently fasted until completion of the test. The average of the serum luteinizing hormone concentrations in the blood samples obtained after 0.5 and 1 hour was considered the early serum luteinizing hormone response, and the average of the values at 16, 20, and 24 hours was considered the late serum luteinizing hormone response. The serum 17α-hydroxyprogesterone concentration at 0 hours was the basal value, and the highest serum 17α-hydroxyprogesterone value after leuprolide administration was considered the peak value.
Assays
Blood samples were centrifuged as soon as they were obtained, and the serum or plasma was stored at –20°C until assayed. The plasma or serum hormones and sex hormone–binding globulin (measured as protein) were assayed as previously described.12 The serum free testosterone concentration was calculated according to the method of Sodergard et al.32 with use of the simultaneously measured serum albumin concentration. To avoid variation between assays, all the samples from an individual woman were analyzed in duplicate in a single assay for each hormone. The intraassay coefficient of variation was 5.5 percent for the plasma insulin assay, 1.6 percent for the serum luteinizing hormone assay, and less than 10 percent for all serum steroid hormone assays.
Plasma concentrations of cholesterol and triglycerides were measured at the Hospital de Clinicas Caracas, and plasma concentrations of high-density lipoprotein and low-density lipoprotein cholesterol were measured by Penn Medical (Washington, D.C.).
Statistical Analysis
The results are reported as means ±SD. Fisher's exact test was used to analyze the differences in ovulation rates between the women who received d-chiro-inositol and those who received placebo. For the other variables, the results were analyzed by comparing the changes in values from base line to the end of the study in the d-chiro-inositol group with the corresponding changes in the placebo group. We tested the distribution of the changes in the two groups for normality with the Wilk–Shapiro test and then compared the changes with use of Student's two-tailed unpaired t-test or the Mann–Whitney rank-sum test. For differences between the groups that were of borderline significance, we also report the within-group comparisons, which were analyzed by Student's two-tailed paired t-test or the Wilcoxon signed-rank test.
The responses of plasma glucose and insulin to the oral administration of glucose and the responses of serum luteinizing hormone and 17α-hydroxyprogesterone after the administration of leuprolide were analyzed by calculating the areas under the response curves by the trapezoidal rule.
Results
Base-Line Characteristics
The base-line clinical and biochemical characteristics of the women in the d-chiro-inositol and placebo groups were similar (Table 1Table 1
Characteristics of 44 Women with the Polycystic Ovary Syndrome at Base Line and after the Administration of d-Chiro-Inositol or Placebo for Six to Eight Weeks. and Figure 1Figure 1Serum Luteinizing Hormone Concentrations in Women with the Polycystic Ovary Syndrome at Base Line and after the Administration of d-Chiro-Inositol or Placebo for Six to Eight Weeks. and Figure 2Figure 2Serum 17α-Hydroxyprogesterone Concentrations in Women with the Polycystic Ovary Syndrome at Base Line and after the Administration of d-Chiro-Inositol or Placebo for Six to Eight Weeks.). Six women in the d-chiro-inositol group had impaired glucose tolerance, as did four women in the placebo group.Anthropometric Measurements and Plasma Lipid Concentrations
The body-mass index did not change in either group during the study, but the change in the waist-to-hip ratio in the d-chiro-inositol group was significantly different from that in the placebo group (P<0.001). In the d-chiro-inositol group, both the decrease in diastolic blood pressure, from 89±5 to 85±6 mm Hg, and the decrease in systolic blood pressure, from 130±7 to 126±7 mm Hg, differed significantly from the corresponding changes in the placebo group (P<0.001 and P=0.05, respectively).
In the d-chiro-inositol group, the plasma total cholesterol concentration decreased significantly (P= 0.03), but this decrease did not differ significantly from the slight increase in the placebo group (P= 0.08) (Table 1). In contrast, the decrease in the plasma triglyceride concentration in the d-chiro-inositol group was significantly greater than that in the placebo group (P=0.002) (Table 1). Plasma high-density and low-density lipoprotein cholesterol concentrations did not change significantly in either group.
Plasma Insulin and Glucose Profiles
There was no statistically significant difference between the decrease in the plasma insulin concentration during fasting in the d-chiro-inositol group and the small increase in the placebo group (Table 1). In the d-chiro-inositol group, the area under the plasma insulin curve after oral glucose administration decreased from 13,417±11,572 to 5158±6714 μU per milliliter per minute (81±69 to 31±40 nmol per liter per minute) (P=0.007), but this decrease did not differ significantly from that in the placebo group (P=0.07).
The plasma glucose concentration during fasting and the area under the plasma glucose curve did not change significantly in either the d-chiro-inositol or the placebo group. However, when the women with impaired glucose tolerance at base line were analyzed separately, the area under the plasma glucose curve decreased from 13,983±3625 to 10,945±2410 mg per deciliter per minute (783±203 to 613±135 mmol per liter per minute) in the d-chiro-inositol group (P=0.03), resulting in normal glucose-tolerance curves in these six women but did not change substantially in four women with impaired glucose tolerance in the placebo group (15,334± 1446 vs. 13,920±1272 mg per deciliter per minute [859±81 vs. 780±71 mmol per liter per minute]) (P=0.18).
Responses of Serum Luteinizing Hormone to Leuprolide
Changes in basal concentrations of serum luteinizing hormone did not differ between the d-chiro-inositol and placebo groups. In contrast, the decrease in the early response of serum luteinizing hormone to leuprolide in the d-chiro-inositol group, from 66±55 mIU per milliliter at base line to 30±15 mIU per milliliter after six to eight weeks of treatment, differed significantly from the change in the placebo group (P=0.05) (Figure 1). Similarly, the decrease in the late response of serum luteinizing hormone to leuprolide in the d-chiro-inositol group, from 103±83 mIU per milliliter at base line to 49±29 mIU per milliliter at six to eight weeks, differed significantly from that in the placebo group (P=0.04).
Responses of Serum 1717α-Hydroxyprogesterone to Leuprolide
The mean basal serum 17α-hydroxyprogesterone concentration did not change significantly with treatment in either the d-chiro-inositol or the placebo group (Figure 2). In the d-chiro-inositol group, the decrease in the peak serum 17α-hydroxyprogesterone concentration after the administration of leuprolide, from 319±212 ng per deciliter at base line to 183±117 ng per deciliter after six to eight weeks (9.6±6.4 to 5.5±3.5 nmol per liter), differed significantly from that in the placebo group (P=0.05). The area under the serum 17α-hydroxyprogesterone curve also decreased, from 5538±3304 to 3103± 1765 ng per deciliter per hour (167±100 to 94±53 nmol per liter per hour), in the d-chiro-inositol group (P=0.006), but this change did not differ significantly from that in the placebo group (P=0.07).
Serum Sex-Steroid Concentrations
The administration of d-chiro-inositol was associated with a decrease in the serum testosterone concentration and an increase in the serum sex hormone–binding globulin concentration (Table 1); both changes differed significantly from those in the placebo group (P=0.003 for both comparisons). This change resulted in a 55 percent decrease in the serum free testosterone concentration in the d-chiro-inositol group, from 1.1±0.8 to 0.5±0.5 ng per deciliter (38±28 to 17±17 pmol per liter), which differed significantly from that in the placebo group (P=0.006). The 47 percent decrease in serum dehydroepiandrosterone sulfate in the d-chiro-inositol group differed significantly from that in the placebo group (P=0.001) (Table 1). The serum concentrations of the other steroids did not change substantially in either group.
Ovulation
Nineteen of the 22 women in the d-chiro-inositol group (86 percent) ovulated during treatment with d-chiro-inositol, as compared with only 6 of the 22 women (27 percent) in the placebo group (P<0.001). The mean peak serum progesterone concentration in the 19 women in the d-chiro-inositol group who ovulated was 12.4±1.7 ng per milliliter (39.4±5.4 nmol per liter). Figure 3Figure 3
Number of Women with the Polycystic Ovary Syndrome Who Ovulated during the Administration of d-Chiro-Inositol or Placebo for Six to Eight Weeks. shows the number of women in the d-chiro-inositol and placebo groups who had serum progesterone concentrations that exceeded 8 ng per milliliter (indicative of ovulation) in weeks 2 through 8.Discussion
In nonhuman primates24 and in humans,25-28 insulin resistance may be related to a deficiency in a putative d-chiro-inositol–containing phosphoglycan mediator of insulin action. The aim of this study was to determine whether the oral administration of d-chiro-inositol would improve insulin sensitivity in a group of insulin-resistant women with the polycystic ovary syndrome. The polycystic ovary syndrome was selected as the model for insulin resistance because it is known that increasing insulin sensitivity in women with this disorder results in improved ovulatory function and decreased serum androgen concentrations.12-14 Moreover, the polycystic ovary syndrome is associated with several other metabolic abnormalities that are also probably linked to insulin resistance; they include glucose intolerance,10,15-17 dyslipidemia,20-22 and hypertension.18,20
We found that the administration of d-chiro-inositol to women with the polycystic ovary syndrome decreased the insulin response to orally administered glucose. Although its cause was not assessed directly in our study, this decrease was most likely due to an improvement in peripheral insulin sensitivity.24-26,28,29 In the women who had impaired glucose tolerance at base line, glucose tolerance improved. Simultaneously with the reduction in insulin secretion, women who received d-chiro-inositol had a striking improvement in ovulatory function: 86 percent of these women ovulated, as compared with only 27 percent of the women who received placebo. Serum androgen concentrations also decreased in the women who received d-chiro-inositol, as did ovarian androgen production, as reflected by a decreased 17α-hydroxyprogesterone response to leuprolide. These findings are consistent with an improvement in insulin sensitivity, as demonstrated previously with drugs such as metformin12,14,33-37 and troglitazone.38,39 The women who received d-chiro-inositol also had decreases in both systolic and diastolic blood pressure and plasma triglyceride concentrations.
Because of technical obstacles, it has not been possible to determine whether the skeletal muscles of women with the polycystic ovary syndrome are deficient in the putative d-chiro-inositol phosphoglycan mediator, but evidence suggests that this is the case in patients with type 2 diabetes mellitus.27,28 A deficiency in this mediator could result from a defect in an epimerase-type enzyme responsible for the intracellular conversion of myo-inositol to chiro-inositol40,41 or, alternatively, from accelerated catabolism of d-chiro-inositol before renal filtration. If either was the case, then exogenous administration of d-chiro-inositol would replenish diminished intracellular d-chiro-inositol stores and restore the d-chiro-inositol phosphoglycan content in skeletal muscle and other insulin target tissues to normal levels.
We conclude that d-chiro-inositol improves ovulatory function and several metabolic abnormalities related to insulin resistance in women with the polycystic ovary syndrome. These observations also suggest that d-chiro-inositol could be used to treat the polycystic ovary syndrome and that d-chiro-inositol may prove useful in the treatment of other disorders that are pathophysiologically related to insulin resistance.
Supported by a Small Business Innovation Research Program grant (R43HD35772) from the National Institutes of Health and by Insmed Pharmaceuticals.
Dr. Nestler has served as a consultant to Insmed Pharmaceuticals.
Source Information
From the Department of Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond (J.E.N.); the Department of Medicine, Hospital de Clinicas Caracas, Caracas, Venezuela (D.J.J.); and Insmed Pharmaceuticals, Richmond, Va. (P.R., R.D.G., G.A.).
Address reprint requests to Dr. Nestler at the Medical College of Virginia, P.O. Box 980111, Richmond, VA 23298-0111, or at nestler@hsc.vcu.edu.
- References
References
1
Eriksson J ,Franssila-Kallunki A ,Ekstrand A , et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989;321:337-343
Full Text | Web of Science | Medline2
Ho LT ,Chang ZY ,Want JT , et al. Insulin insensitivity in offspring of parents with type 2 diabetes mellitus. Diabet Med 1990;7:31-34
CrossRef | Web of Science | Medline3
Lillioja S ,Mott DM ,Spraul M , et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 1993;329:1988-1992
Full Text | Web of Science | Medline4
Warram JH ,Martin BC ,Krolewski AS ,Soeldner JS ,Kahn CR . Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990;113:909-915
Web of Science | Medline5
Reaven GM . Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 1988;37:1595-1607
CrossRef | Web of Science | Medline6
Reaven GM . Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension: parallels between human disease and rodent models. Diabetes Care 1991;14:195-202
CrossRef | Web of Science | Medline7
Zavaroni I ,Bonora E ,Pagliara M , et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989;320:702-706
Full Text | Web of Science | Medline8
Dunaif A ,Graf M ,Mandeli J ,Laumas V ,Dobrjansky A . Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987;65:499-507
CrossRef | Web of Science | Medline9
Dunaif A ,Segal KR ,Futterweit W ,Dobrjansky A . Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-1174
CrossRef | Web of Science | Medline10
Ehrmann DA ,Sturis J ,Byrne MM ,Karrison T ,Rosenfield RL ,Polonsky KS . Insulin secretory defects in polycystic ovary syndrome: relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 1995;96:520-527
CrossRef | Web of Science | Medline11
Franks S . Polycystic ovary syndrome. N Engl J Med 1995;333:853-861[Erratum, N Engl J Med 1995;333:1435.]
Full Text | Web of Science | Medline12
Nestler JE ,Jakubowicz DJ ,Evans WS ,Pasquali R . Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-1880
Full Text | Web of Science | Medline13
Nestler JE ,Jakubowicz DJ . Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens. J Clin Endocrinol Metab 1997;82:4075-4079
CrossRef | Web of Science | Medline14
Nestler JE ,Jakubowicz DJ . Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617-623
Full Text | Web of Science | Medline15
Dahlgren E ,Johansson S ,Lindstedt G , et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992;57:505-513
Web of Science | Medline16
Ehrmann DA ,Barnes RB ,Rosenfield RL ,Cavaghan MK ,Imperial J . Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141-146
CrossRef | Web of Science | Medline17
Legro RS ,Finegood D ,Dunaif A . A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2694-2698
CrossRef | Web of Science | Medline18
Bjorntorp P . The android woman -- a risky condition. J Intern Med 1996;239:105-110
CrossRef | Web of Science | Medline19
Dahlgren E ,Janson PO ,Johansson S ,Lapidus L ,Oden A . Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599-604
CrossRef | Web of Science | Medline20
Rebuffe-Scrive M ,Cullberg G ,Lundberg P-A ,Lindstedt G ,Bjorntorp P . Anthropometric variables and metabolism in polycystic ovarian disease. Horm Metab Res 1989;21:391-397
CrossRef | Web of Science | Medline21
Wild RA ,Alaupovic P ,Parker IJ . Lipid and apolipoprotein abnormalities in hirsute women. I. The association with insulin resistance. Am J Obstet Gynecol 1992;166:1191-1197[Erratum, J Obstet Gynecol 1992;167:575.]
Web of Science | Medline22
Wild RA . Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med 1995;98:Suppl 1A:27S-32S
CrossRef | Web of Science | Medline23
Larner J . Multiple pathways in insulin signalling -- fitting the covalent and allosteric puzzle pieces together. Endocr J 1994;2:167-17124
Ortmeyer HK ,Bodkin NL ,Lilley K ,Larner J ,Hansen BC . Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys. Endocrinology 1993;132:640-645
CrossRef | Web of Science | Medline25
Suzuki S ,Kawasaki H ,Satoh Y , et al. Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes. Diabetes Care 1994;17:1465-1468
CrossRef | Web of Science | Medline26
Craig JW, Larner J, Asplin CM. Chiro-inositol deficiency and insulin resistance. In: Draznin B, LeRoith D, eds. Molecular biology of diabetes. Part 2. Totowa, N.J.: Humana Press, 1994:343-62.
27
Kennington AS ,Hill CR ,Craig J , et al. Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1990;323:373-378
Full Text | Web of Science | Medline28
Asplin I ,Galasko G ,Larner J . Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci U S A 1993;90:5924-5928
CrossRef | Web of Science | Medline29
Ortmeyer HK ,Huang LC ,Zhang L ,Hansen BC ,Larner J . Chiroinositol deficiency and insulin resistance. II. Acute effects of D-chiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin-resistant rhesus monkeys. Endocrinology 1993;132:646-651
CrossRef | Web of Science | Medline30
Yeh HC ,Futterweit W ,Thornton JC . Polycystic ovarian disease: US features in 104 patients. Radiology 1987;163:111-116
Web of Science | Medline31
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
Web of Science | Medline32
Sodergard R ,Backstrom T ,Shanbhag V ,Carstensen H . Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature. J Steroid Biochem 1982;16:801-810
CrossRef | Medline33
Diamanti-Kandarakis E ,Kouli C ,Tsianateli T ,Bergiele A . Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998;138:269-274
CrossRef | Web of Science | Medline34
Morin-Papunen LC ,Koivunen RM ,Ruokonen A ,Martikainen HK . Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998;69:691-696
CrossRef | Web of Science | Medline35
Velazquez E ,Acosta A ,Mendoza SG . Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997;90:392-395
CrossRef | Web of Science | Medline36
Velazquez EM ,Mendoza S ,Hamer T ,Sosa F ,Glueck CJ . Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-654
CrossRef | Web of Science | Medline37
Velazquez EM ,Mendoza SG ,Wang P ,Glueck CJ . Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 1997;46:454-457
CrossRef | Web of Science | Medline38
Dunaif A ,Scott D ,Finegood D ,Quintana B ,Whitcomb R . The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:3299-3306
CrossRef | Web of Science | Medline39
Ehrmann DA ,Schneider DJ ,Sobel BE , et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2108-2116
CrossRef | Web of Science | Medline40
Pak Y ,Huang LC ,Lilley KJ ,Larner J . In vivo conversion of [3H]myoinositol to [3H]chiroinositol in rat tissues. J Biol Chem 1992;267:16904-16910
Web of Science | Medline41
Pak Y ,Paule CR ,Bao YD ,Huang LC ,Larner J . Insulin stimulates the biosynthesis of chiro-inositol-containing phospholipids in a rat fibroblast line expressing the human insulin receptor. Proc Natl Acad Sci U S A 1993;90:7759-7763
CrossRef | Web of Science | Medline
- Citing Articles (103)
Citing Articles
1
V Unfer, G Carlomagno, G Dante, F Facchinetti. (2012) Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecological Endocrinology1-7
CrossRef2
A. Santamaria, D. Giordano, F. Corrado, B. Pintaudi, M. L. Interdonato, G. Di Vieste, A. Di Benedetto, R. D'Anna. (2011) One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Climacteric1-6
CrossRef3
Yang YAO, Xu-zhen CHENG, Gui-xing REN. (2011) Application of Near-Infrared Reflectance Spectroscopy to the Evaluation of D-chiro-lnositol, Vitexin, and Isovitexin Contents in Mung Bean. Agricultural Sciences in China 10:12, 1986-1991
CrossRef4
R. D’Anna, V. Di Benedetto, P. Rizzo, E. Raffone, M.L. Interdonato, F. Corrado, A. Di Benedetto. (2011) Myo-inositol may prevent gestational diabetes in PCOS women. Gynecological Endocrinology1-3
CrossRef5
Punuri Jayasekhar Babu, Pragya Sharma, Mohan Chandra Kalita, Utpal Bora. (2011) Green synthesis of biocompatible gold nanoparticles using Fagopyrum esculentum leaf extract. Frontiers of Materials Science
CrossRef6
Pietro Cavalli, Gabriele Tonni, Enrico Grosso, Carlo Poggiani. (2011) Effects of inositol supplementation in a cohort of mothers at risk of producing an NTD pregnancy. Birth Defects Research Part A: Clinical and Molecular Teratology 91:11, 962-965
CrossRef7
Thozhukat Sathyapalan, Stephen L Atkin. (2011) The link between polycystic ovary syndrome and Type 2 diabetes: what do we know today?. Diabetes Management 1:6, 641-652
CrossRef8
Massimo Minozzi, Demetrio Costantino, Claudia Guaraldi, Vittorio Unfer. (2011) The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecological Endocrinology 27:11, 920-924
CrossRef9
Rina Agrawal, Elizabeth Burt, Anne Marie Gallagher, Lisa Butler, Radha Venkatakrishnan, Panagiotis Peitsidis. (2011) Prospective randomized trial of multiple micronutrients in subfertile women undergoing ovulation induction: a pilot study. Reproductive BioMedicine Online
CrossRef10
J. M. Pauli, N. Raja-Khan, X. Wu, R. S. Legro. (2011) Current perspectives of insulin resistance and polycystic ovary syndrome. Diabetic Medicineno-no
CrossRef11
F. Corrado, R. D’Anna, G. Di Vieste, D. Giordano, B. Pintaudi, A. Santamaria, A. Di Benedetto. (2011) The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabetic Medicine 28:8, 972-975
CrossRef12
Patrizia De Marco, Elisa Merello, Armando Cama, Zoha Kibar, Valeria Capra. (2011) Human neural tube defects: Genetic causes and prevention. BioFactors 37:4, 261-268
CrossRef13
Giuseppe Morgante, Raoul Orvieto, Alessandra Di Sabatino, Maria C. Musacchio, Vincenzo De Leo. (2011) The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. Fertility and Sterility 95:8, 2642-2644
CrossRef14
Gianfranco Carlomagno, Vittorio Unfer, Scott Roseff. (2011) The D-chiro-inositol paradox in the ovary. Fertility and Sterility 95:8, 2515-2516
CrossRef15
Pietro Rizzo, Emanuele Raffone. (2011) Comments on the role of inositol supplementation in patients with polycystic ovary syndrome. Fertility and Sterility 95:7, e48
CrossRef16
Nicolas Galazis, Myria Galazi, William Atiomo. (2011)
d -Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review. Gynecological Endocrinology 27:4, 256-262
CrossRef17
Baoru Yang, Jie Zheng, Heikki Kallio. (2011) Influence of origin, harvesting time and weather conditions on content of inositols and methylinositols in sea buckthorn (Hippophaë rhamnoides) berries. Food Chemistry 125:2, 388-396
CrossRef18
Stephen Franks. (2011) When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome?. Clinical Endocrinology 74:2, 148-151
CrossRef19
Masaru Yamaoka, Shin Osawa, Tetsuro Morinaga, Shinji Takenaka, Ken-ichi Yoshida. (2011) A cell factory of Bacillus subtilis engineered for the simple bioconversion of myo-inositol to scyllo-inositol, a potential therapeutic agent for Alzheimer's disease. Microbial Cell Factories 10:1, 69
CrossRef20
Domenico Giordano, Francesco Corrado, Angelo Santamaria, Simona Quattrone, Basilio Pintaudi, Antonino Di Benedetto, Rosario D'Anna. (2011) Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Menopause 18:1, 102-104
CrossRef21
Lekha Saha, Sharonjeet Kaur, Pradip Kumar Saha. (2011) Pharmacotherapy of polycystic ovary syndrome - an update. Fundamental & Clinical Pharmacologyno-no
CrossRef22
Umeo Takahama, Mariko Tanaka, Sachiko Hirota. 2011. Buckwheat Flour and Bread. , 141-151.
CrossRef23
Jui-Tung Chen, Kunihiko Tominaga, Yoshiaki Sato, Hideo Anzai, Ryo Matsuoka. (2010) Maitake Mushroom ( Grifola frondosa ) Extract Induces Ovulation in Patients with Polycystic Ovary Syndrome: A Possible Monotherapy and a Combination Therapy After Failure with First-Line Clomiphene Citrate. The Journal of Alternative and Complementary Medicine 16:12, 1295-1299
CrossRef24
Wei Tang, Huazong Zeng, Yongquan Shi, Zhimin Liu, Jinwei Cheng, Juan Xu, Wei Tang. 2010. Corticosteroids, somatostatin analogous or orbital radiotherapy for thyroid-associated ophthalmopathy. .
CrossRef25
Elvia Coballase-Urrutia, José Pedraza-Chaverri, Rafael Camacho-Carranza, Noemí Cárdenas-Rodríguez, Bernardino Huerta-Gertrudis, Omar Noel Medina-Campos, Myrna Mendoza-Cruz, Guillermo Delgado-Lamas, J. Javier Espinosa-Aguirre. (2010) Antioxidant activity of Heterotheca inuloides extracts and of some of its metabolites. Toxicology 276:1, 41-48
CrossRef26
Liulin Tang, Liangzhi Xu, Xin Pan, Jing Zhang, Taixiang Wu, Guan J Liu, Liangzhi Xu. 2010. Ultrasound-guided transvaginal ovarian needle drilling for clomiphene-resistant polycystic ovarian syndrome in subfertile women. .
CrossRef27
Anthony Fardet. (2010) New hypotheses for the health-protective mechanisms of whole-grain cereals: what is beyond fibre?. Nutrition Research Reviews 23:01, 65-134
CrossRef28
Jean-Patrice Baillargeon, Maria J. Iuorno, Teimuraz Apridonidze, John E. Nestler. (2010) Uncoupling Between Insulin and Release of a
d - Chiro -Inositol–Containing Inositolphosphoglycan Mediator of Insulin Action in Obese Women With Polycystic Ovary Syndrome. Metabolic Syndrome and Related Disorders 8:2, 127-136
CrossRef29
Cindy Farquhar, Tang Ying, Taixiang Wu, Xu Liangzhi. 2010. Laparoscopic ovarian diathermy versus metformin for women with polycystic ovarian syndrome. .
CrossRef30
Marie-Hélène Massicotte, Fabienne Langlois, Jean-Patrice Baillargeon. (2010) Current procedures for managing polycystic ovary syndrome. Expert Review of Obstetrics & Gynecology 5:1, 77-91
CrossRef31
Nhung Thuy DANG, Rie MUKAI, Ken-ichi YOSHIDA, Hitoshi ASHIDA. (2010) D-Pinitol and myo-Inositol Stimulate Translocation of Glucose Transporter 4 in Skeletal Muscle of C57BL/6 Mice. Bioscience, Biotechnology, and Biochemistry 74:5, 1062-1067
CrossRef32
Goverdhan Mehta, Saikat Sen. (2010) From aromatics to conjoined inositols: stereoselective oxyfunctionalization of anthracene. Tetrahedron Letters 51:3, 503-507
CrossRef33
E. Papaleo, V. Unfer, J.P. Baillargeon, T.T. Chiu. (2009) Contribution of myo-inositol to reproduction. European Journal of Obstetrics & Gynecology and Reproductive Biology 147:2, 120-123
CrossRef34
Thomas Tang, Jonathan M Lord, Robert J Norman, Ephia Yasmin, Adam H Balen, Adam H Balen. 2009. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. .
CrossRef35
Gabriella Garruti, Raffaella Depalo, Maria Grazia Vita, Filomenamila Lorusso, Federica Giampetruzzi, Aurelia Bellomo Damato, Francesco Giorgino. (2009) Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment. Reproductive BioMedicine Online 19:4, 552-563
CrossRef36
Marco Scioscia, Khalid Gumaa, Luigi E. Selvaggi, Charles H. Rodeck, Thomas W. Rademacher. (2009) Increased inositol phosphoglycan P-type in the second trimester in pregnant women with type 2 and gestational diabetes mellitus. Journal of Perinatal Medicine 37:5, 469-471
CrossRef37
Marie-Claude Villeneuve, Richard E. Ostlund, Jean-Patrice Baillargeon. (2009) Hyperinsulinemia is closely related to low urinary clearance of d-chiro-inositol in men with a wide range of insulin sensitivity. Metabolism 58:1, 62-68
CrossRef38
R. Jeffrey Chang. 2009. Polycystic Ovary Syndrome and Hyperandrogenic States. , 489-516.
CrossRef39
Héctor F Escobar Morreale. (2008) Polycystic ovary syndrome: treatment strategies and management. Expert Opinion on Pharmacotherapy 9:17, 2995-3008
CrossRef40
Kai I. Cheang, Jean-Patrice Baillargeon, Paulina A. Essah, Richard E. Ostlund, Teimuraz Apridonize, Leila Islam, John E. Nestler. (2008) Insulin-stimulated release of d-chiro-inositol–containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 57:10, 1390-1397
CrossRef41
2008. Anovulatory infertility and ovulation induction. , 123-178.
CrossRef42
Pietro Cavalli, Sara Tedoldi, Barbara Riboli. (2008) Inositol supplementation in pregnancies at risk of apparently folate-resistant NTDs. Birth Defects Research Part A: Clinical and Molecular Teratology 82:7, 540-542
CrossRef43
Gladys Nuissier, Faïza Diaba, Micheline Grignon-Dubois. (2008) Bioactive agents from beach waste: Syringodium flotsam evaluation as a new source of l-chiro-inositol. Innovative Food Science & Emerging Technologies 9:3, 396-400
CrossRef44
Andrea Dunaif. (2008) Drug Insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome—a reappraisal. Nature Clinical Practice Endocrinology & Metabolism 4:5, 272-283
CrossRef45
M Minozzi, G D'Andrea, V Unfer. (2008) Treatment of hirsutism with myo-inositol: a prospective clinical study. Reproductive BioMedicine Online 17:4, 579-582
CrossRef46
Marco Scioscia, Khalid Gumaa, Melissa Whitten, Luigi E. Selvaggi, Charles H. Rodeck, Thomas W. Rademacher. (2007) Inositol phosphoglycan P-type in healthy and preeclamptic pregnancies. Journal of Reproductive Immunology 76:1-2, 85-90
CrossRef47
J.-P. Baillargeon, A. C. Carpentier. (2007) Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects. Diabetologia 50:12, 2424-2432
CrossRef48
M. Scioscia, S. Kunjara, K. Gumaa, P. McLean, C. H. Rodeck, T. W. Rademacher. (2007) Urinary excretion of inositol phosphoglycan P-type in gestational diabetes mellitus. Diabetic Medicine 24:11, 1300-1304
CrossRef49
Mi Jin Kim, Kwang Ha Yoo, Ji Hoon Kim, Young Tak Seo, Byung Wook Ha, Jang Hyun Kho, Young Goo Shin, Choon Hee Chung. (2007) Effect of pinitol on glucose metabolism and adipocytokines in uncontrolled type 2 diabetes. Diabetes Research and Clinical Practice 77:3, S247-S251
CrossRef50
Robert J Norman, Didier Dewailly, Richard S Legro, Theresa E Hickey. (2007) Polycystic ovary syndrome. The Lancet 370:9588, 685-697
CrossRef51
Daniela Fenili, Mary Brown, Rebecca Rappaport, JoAnne McLaurin. (2007) Properties of scyllo–inositol as a therapeutic treatment of AD-like pathology. Journal of Molecular Medicine 85:6, 603-611
CrossRef52
Ephia Yasmin, Adam H Balen. (2007) Management of polycystic ovary syndrome. Women's Health 3:3, 355-367
CrossRef53
Karim Lahjouji, Rym Aouameur, Pierre Bissonnette, Michael J. Coady, Daniel G. Bichet, Jean-Yves Lapointe. (2007) Expression and functionality of the Na+/myo-inositol cotransporter SMIT2 in rabbit kidney. Biochimica et Biophysica Acta (BBA) - Biomembranes 1768:5, 1154-1159
CrossRef54
Legro, Richard S., Barnhart, Huiman X., Schlaff, William D., Carr, Bruce R., Diamond, Michael P., Carson, Sandra A., Steinkampf, Michael P., Coutifaris, Christos, McGovern, Peter G., Cataldo, Nicholas A., Gosman, Gabriella G., Nestler, John E., Giudice, Linda C., Leppert, Phyllis C., Myers, Evan R., . (2007) Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome. New England Journal of Medicine 356:6, 551-566
Full Text55
Cindy Farquhar, Tang Ying, Taixiang Wu, Xu Liangzhi. 2006. Laparoscopic ovarian diathermy versus metformin for women with polycystic ovarian syndrome. .
CrossRef56
R HART, R NORMAN. (2006) Polycystic ovarian syndrome – prognosis and outcomes. Best Practice & Research Clinical Obstetrics & Gynaecology 20:5, 751-778
CrossRef57
Chris D. Meletis, Nieske Zabriskie. (2006) Natural Approaches for Treating Polycystic Ovary Syndrome. Alternative and Complementary Therapies 12:4, 157-164
CrossRef58
Robert P. Kauffman, Vicki M. Baker, Pamela DiMarino, V. Daniel Castracane. (2006) Hyperinsulinemia and circulating dehydroepiandrosterone sulfate in white and Mexican American women with polycystic ovary syndrome. Fertility and Sterility 85:4, 1010-1016
CrossRef59
Pascal Froment, Philippe Touraine. (2006) Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS). PPAR Research 2006, 1-8
CrossRef60
Charles W. Gray, Leland L. Johnson, Brian T. Walker, Mark C. Sleevi, A. Stewart Campbell, Robert Plourde, Todd A. Houston. (2005) Specific sensing between inositol epimers by a bis(boronate). Bioorganic & Medicinal Chemistry Letters 15:24, 5416-5418
CrossRef61
M.L. Cruz, G.Q. Shaibi, M.J. Weigensberg, D. Spruijt-Metz, G.D.C. Ball, M.I. Goran. (2005) PEDIATRIC OBESITY AND INSULIN RESISTANCE: Chronic Disease Risk and Implications for Treatment and Prevention Beyond Body Weight Modification. Annual Review of Nutrition 25:1, 435-468
CrossRef62
Takashi Ueda, Mark P. Coseo, Thomas J. Harrell, Ralph L. Obendorf. (2005) A multifunctional galactinol synthase catalyzes the synthesis of fagopyritol A1 and fagopyritol B1 in buckwheat seed. Plant Science 168:3, 681-690
CrossRef63
Tae-Sik Jung, Jong-Ryeal Hahm, Jong-Jin Kim, Jung-Hwa Jung, Mi-Yeon Kang, Sung-Won Moon, Kang-Wan Lee, Ho-Cheol Kim, Jong-Deog Lee, Ji-Hye Kim, Deok-Ryong Kim, Soon-Il Chung. (2005) Determination of Urinary Myo -/ Chiro -Inositol Ratios from Korean Diabetes Patients. Yonsei Medical Journal 46:4, 532
CrossRef64
Bulent O Yildiz. (2004) Recent advances in the treatment of polycystic ovary syndrome. Expert Opinion on Investigational Drugs 13:10, 1295-1305
CrossRef65
Marzieh Salehi, Rafael Bravo-Vera, Arsalan Sheikh, Alina Gouller, Leonid Poretsky. (2004) Pathogenesis of polycystic ovary syndrome: what is the role of obesity?. Metabolism 53:3, 358-376
CrossRef66
Emre Seli, Antoni J. Duleba. (2004) Treatment of PCOS with metformin and other insulin-sensitizing agents. Current Diabetes Reports 4:1, 69-75
CrossRef67
Bel??n Rold??n, Jos?? L San Mill??n, H??ctor F Escobar-Morreale. (2004) Genetic Basis of Metabolic Abnormalities in Polycystic Ovary Syndrome. American Journal of PharmacoGenomics 4:2, 93-107
CrossRef68
Ricardo Azziz. (2004) PCOS: a diagnostic challenge. Reproductive BioMedicine Online 8:6, 644-648
CrossRef69
Annika K. Schröder, Sascha Tauchert, Olaf Ortmann, Klaus Diedrich, Jürgen M. Weiss. (2003) Die Insulinresistenz beim polyzystischen Ovar-Syndrom. Wiener Klinische Wochenschrift 115:23, 812-821
CrossRef70
VINCENZA BRUNI, METELLA DEI, VALENTINA PONTELLO, PAOLO VANGELISTI. (2003) The Management of Polycystic Ovary Syndrome. Annals of the New York Academy of Sciences 997:1, 307-321
CrossRef71
EVANTHIA DIAMANTI-KANDARAKIS, HELEN A. KANDARAKIS. (2003) Conservative Management of Gynecologic Diseases. Annals of the New York Academy of Sciences 997:1, 322-329
CrossRef72
Tevfik Sabuncu, Muge Harma, Mehmet Harma, Yasar Nazligul, Feryal Kilic. (2003) Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertility and Sterility 80:5, 1199-1204
CrossRef73
Ricardo Azziz. (2003) Androgen excess is the key element in polycystic ovary syndrome. Fertility and Sterility 80:2, 252-254
CrossRef74
S PFEIFER, M DAYAL. (2003) Treatment of the adolescent patient with polycystic ovary syndrome. Obstetrics and Gynecology Clinics of North America 30:2, 337-352
CrossRef75
Lyndal Harborne, Richard Fleming, Helen Lyall, Jane Norman, Naveed Sattar. (2003) Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. The Lancet 361:9372, 1894-1901
CrossRef76
I. N. Stanciu, S. Pitale, R. A. Prinz, S. Jakate, G. Webb, D. Steiner, S. Braithwaite, D. Gordon, M. A. Emanuele. (2003) Insulinoma presenting with hyperandrogenism: a case report and a literature review. Journal of Internal Medicine 253:4, 484-489
CrossRef77
Paolo Moghetti. (2002) Insulin resistance: what is its role in the polycystic ovary syndrome?. Current Opinion in Endocrinology & Diabetes 9:6, 444-450
CrossRef78
Jessica K. Wickenheisser, Jerome F. Strauss, Jan M. McAllister. (2002) Steroidogenic abnormalities in ovarian theca cells in polycystic ovary syndrome. Current Opinion in Endocrinology & Diabetes 9:6, 486-491
CrossRef79
J WEISWASSER, E NYLEN, S ARORA, M WAKEFIELD, A SIDAWY. (2002) Syndrome X and diabetes: What is the mystery?. Seminars in Vascular Surgery 15:4, 216-224
CrossRef80
Giorgio Catelani, Antonino Corsaro, Felicia D'Andrea, Manuela Mariani, Venerando Pistarà. (2002) Intramolecular aldol cyclization of l-lyxo-Hexos-5-ulose derivatives: A new diastereoselective synthesis of d-chiro-Inositol. Bioorganic & Medicinal Chemistry Letters 12:22, 3313-3315
CrossRef81
George P. N. Samraj, Louis Kuritzky. (2002) Polycystic ovary syndrome [PCOS]: Comprehensive management in primary care. Comprehensive Therapy 28:3, 208-221
CrossRef82
Elizabeth Anna Pritts. (2002) Treatment of the Infertile Patient With Polycystic Ovarian Syndrome. Obstetrical & Gynecological Survey 57:9, 587-597
CrossRef83
Ping Wang, Patricia Streicher, Charles J Glueck. (2002) Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opinion on Pharmacotherapy 3:8, 1177-1189
CrossRef84
Elizabeth E. Baumann, Robert L. Rosenfield. (2002) Polycystic Ovary Syndrome in Adolescence. The Endocrinologist 12:4, 333-348
CrossRef85
John R Petrie, Colin G Perry. (2002) Insulin-sensitising agents: beyond thiazolidinediones. Expert Opinion on Emerging Drugs 7:1, 165-174
CrossRef86
John E. Nestler, Dale Stovall, Nausheen Akhter, Maria J. Iuorno, Daniela J. Jakubowicz. (2002) Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertility and Sterility 77:2, 209-215
CrossRef87
Silva A. Arslanian, Selma F. Witchel. (2002) Polycystic ovary syndrome in adolescents: is there an epidemic?. Current Opinion in Endocrinology & Diabetes 9:1, 32-42
CrossRef88
Fahri Bayram, Kursad Unluhizarci, Fahrettin Kelestimur. (2002) Potential Utility of Insulin Sensitizers in the Treatment of Patients with Polycystic Ovary Syndrome. Treatments in Endocrinology 1:1, 45-53
CrossRef89
Paolo Moghetti. (2001) Advances in the treatment of polycystic ovary syndrome. Expert Opinion on Investigational Drugs 10:9, 1631-1640
CrossRef90
M IUORNO, J NESTLER. (2001) Insulin-Lowering Drugs In Polycystic Ovary Syndrome. Obstetrics and Gynecology Clinics of North America 28:1, 153-164
CrossRef91
W PHIPPS. (2001) Polycystic Ovary Syndrome And Ovulation Induction. Obstetrics and Gynecology Clinics of North America 28:1, 165-182
CrossRef92
H ZACUR. (2001) Polycystic Ovary Syndrome Hyperandrogenism, and Insulin Resistance. Obstetrics and Gynecology Clinics of North America 28:1, 21-33
CrossRef93
David T Vandermolen, Valerie S Ratts, William S Evans, Dale W Stovall, Scott W Kauma, John E Nestler. (2001) Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility 75:2, 310-315
CrossRef94
Yoshiaki Takahashi, Hitoshi Nakayama, Keiki Katagiri, Kumi Ichikawa, Nobuhiro Ito, Tomohisa Takita, Tomio Takeuchi, Toshiaki Miyake. (2001) Facile and practical synthesis of optically pure 1d-chiro-inositol from myo-inositol. Tetrahedron Letters 42:6, 1053-1056
CrossRef95
Andrea Dunaif, Abraham Thomas. (2001) C
URRENT CONCEPTS IN THE POLYCYSTIC OVARY SYNDROME . Annual Review of Medicine 52:1, 401-419
CrossRef96
John E. Nestler. (2000) Insulin resistance and the polycystic ovary syndrome: recent advances. Current Opinion in Endocrinology & Diabetes 7:6, 345-349
CrossRef97
A TAYLOR. (2000) INSULIN-LOWERING MEDICATIONS IN POLYCYSTIC OVARY SYNDROME. Obstetrics and Gynecology Clinics of North America 27:3, 583-595
CrossRef98
D HOCK, D SEIFER. (2000) NEW TREATMENTS OF HYPERANDROGENISM AND HIRSUTISM. Obstetrics and Gynecology Clinics of North America 27:3, 567-581
CrossRef99
Haim Einat, Alona Shaldubina, R.H. Belmaker. (2000) Epi-inositol: A potential antidepressant. Drug Development Research 50:3-4, 309-315
CrossRef100
BARBARA CALEEN HANSEN. (1999) The Metabolic Syndrome X. Annals of the New York Academy of Sciences 892:1 THE METABOLIC, 1-24
CrossRef101
Adam Balen. (1999) Pathogenesis of polycystic ovary syndrome—the enigma unravels?. The Lancet 354:9183, 966-967
CrossRef102
Allen W. Root. (1999) Endocrine and metabolism. Current Opinion in Pediatrics 11:4, 329-332
CrossRef103
Maria J. Iuorno, John E. Nestler. (1999) The polycystic ovary syndrome: treatment with insulin sensitizing agents. Diabetes, Obesity and Metabolism 1:3, 127-136
CrossRef
